A selective Y1R ligand (Asn6, Pro34-NPY) co-administered with tariquidar (a P-glycoprotein inhibitor) exerted a synergistic effect and improved the therapeutic efficacy against multidrug-resistant breast cancer cells [108]. The gene discussed is ABCB1; the disease is breast carcinoma.